Advertisement

Clinical Drug Investigation

, Volume 39, Issue 2, pp 231–231 | Cite as

Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

  • Sohita DhillonEmail author
Correction
  • 34 Downloads

1 Correction to: Clin Drug Investig (2019)  https://doi.org/10.1007/s40261-018-0741-2

An Online First version of this article was made available online at https://rd.springer.com/article/10.1007%2Fs40261-018-0741-2 on 3 January 2019. An error was subsequently identified in the article, and the following correction should be noted:

Correction to Fig. 1 caption

The caption of Fig. 1, which previously read:

Fig. 1 Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. E oestrogen, ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2”

Should read:

Fig. 1 Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. E oestrogen, ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2. © Puma Biotechnology, 2018 (published with permission)”

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations